Invex Therapeutics (ASX:IXC) Current Accrued Expense: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IXC Invex Therapeutics Ltd ASX:IXC
32 GF Score
Price A$0.12
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Current Accrued Expense?

Invex Therapeutics ASX:IXC 32 Current Accrued Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Invex Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Invex Therapeutics Current Accrued Expense Related Terms

Invex Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Current Accrued Expense Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Accrued Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:IXC
32GF Score
Invex Therapeutics Ltd ASX:IXC
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a Current Accrued Expense of A$0.00 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Current Accrued Expense too high?
Invex Therapeutics' current Current Accrued Expense is A$0.00 Mil. Overall, Invex Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Current Accrued Expense compare to VRTX and REGN?
Invex Therapeutics' Current Accrued Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Current Accrued Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Current Accrued Expense of A$0.00 Mil. The current Current Accrued Expense is A$0.00 Mil. Invex Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Current Accrued Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
32GF Score

Get the complete analysis for ASX:IXC

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price